Rivfloza

Active Ingredient(s): Nedosiran Sodium
FDA Approved: * September 29, 2023
Pharm Company: * NOVO NORDISK INC
Category: Genetic Disorders
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Rivfloza 160 mg/ml Subcutaneous Injection, Solution
NDC: 0169-5306
Labeler:
Novo Nordisk
Rivfloza 128 mg/.8ml Subcutaneous Injection, Solution
NDC: 0169-5307
Labeler:
Novo Nordisk
Rivfloza 80 mg/.5ml Subcutaneous Injection, Solution
NDC: 0169-5308
Labeler:
Novo Nordisk